Sandbox Reserved 1474: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 94: | Line 94: | ||
===Human-mouse chimeric monoclonal antibody(mAb) Ch-mAb7F9=== | ===Human-mouse chimeric monoclonal antibody(mAb) Ch-mAb7F9=== | ||
IgG mAbs are typically chimeric, humanized, or fully human proteins. The longest t1/2lamdaz values are usually achieved when the antibody does not bind to tissue sites and is not prematurely cleared due to antigenicity. | IgG mAbs are typically chimeric, humanized, or fully human proteins. The longest t1/2lamdaz values are usually achieved when the antibody does not bind to tissue sites and is not prematurely cleared due to antigenicity<>. | ||
Ch-mAb7F9, a chimeric mAb is produced as a treatment medication for METH abuse based on the murine anti-METH mAb7F9. It is created by preserving mAb7f9 variable region with human IgG2 constant domains to minimize the risk of effector function. In vitro, it is shown only binds to (+)METH (KD=6.9nM), (+)AMP(KI = 350 nM), (+)MDMA(kI=6.7nM). | Ch-mAb7F9, a chimeric mAb is produced as a treatment medication for METH abuse based on the murine anti-METH mAb7F9<ref name="Pharmacological effects of two anti-methamphetamine monoclonal antibodies"/>. It is created by preserving mAb7f9 variable region with human IgG2 constant domains<ref name="Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use" /> | ||
to minimize the risk of effector function. In vitro, it is shown only binds to (+)METH (KD=6.9nM)<ref name="Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use" /> | |||
, (+)AMP(KI = 350 nM)<ref name="Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use" /> | |||
, (+)MDMA(kI=6.7nM)<ref name="Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use" /> | |||
. | |||
